A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2018
At a glance
- Drugs Gilteritinib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 22 Oct 2018 Status changed from not yet recruiting to recruiting.
- 21 Sep 2018 Planned End Date changed from 9 Jul 2021 to 11 Oct 2021.
- 21 Sep 2018 Planned primary completion date changed from 5 Jul 2021 to 9 Jan 2021.